Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 30;11(11):CD007652.
doi: 10.1002/14651858.CD007652.pub7.

Gene therapy for sickle cell disease

Abiola Olowoyeye  1 , Charles I Okwundu  2
Affiliations

Gene therapy for sickle cell disease

Abiola Olowoyeye et al. Cochrane Database Syst Rev. .

Abstract

Background: Sickle cell disease encompasses a group of genetic disorders characterized by the presence of at least one hemoglobin S (Hb S) allele, and a second abnormal allele that could allow abnormal haemoglobin polymerisation leading to a symptomatic disorder. Autosomal recessive disorders (such as sickle cell disease) are good candidates for gene therapy because a normal phenotype can be restored in diseased cells with only a single normal copy of the mutant gene. This is an update of a previously published Cochrane Review.

Objectives: The objectives of this review are: - to determine whether gene therapy can improve survival and prevent symptoms and complications associated with sickle cell disease; - to examine the risks of gene therapy against the potential long-term gain for people with sickle cell disease.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, which comprises of references identified from comprehensive electronic database searches and searching relevant journals and abstract books of conference proceedings. We also searched online trial registries, Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 21 September 2020.

Selection criteria: All randomised or quasi-randomised clinical trials (including any relevant phase 1, 2 or 3 trials) of gene therapy for all individuals with sickle cell disease, regardless of age or setting.

Data collection and analysis: No trials of gene therapy for sickle cell disease were found.

Main results: No trials of gene therapy for sickle cell disease were reported.

Authors' conclusions: No randomised or quasi-randomised clinical trials of gene therapy for sickle cell disease were reported. Thus, no objective conclusions or recommendations in practice can be made on gene therapy for sickle cell disease. This systematic review has identified the need for well-designed, randomised controlled trials to assess the benefits and risks of gene therapy for sickle cell disease.

PubMed Disclaimer

Conflict of interest statement

Both authors: none known.

Update of

Similar articles

See all similar articles

Cited by

References

Additional references

Akinyanju 1989
    1. Akinyanju OO. A profile of sickle cell disease in Nigeria. Annals of the New York Academy of Sciences 1989;565:126-36. - PubMed
Bodine 2003
    1. Bodine DM. Gene therapy for sickle cell disease marches on. Blood 2003;102:4247.
Chang 2006
    1. Chang JC, Kan YW. Correction of the sickle cell mutation in embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America 2006;103(4):1036-40. - PMC - PubMed
Gaston 1986
    1. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. New England Journal of Medicine 1986;314(25):1593-9. - PubMed
Goncz 2002
    1. Goncz KK, Prokopishyn NL, Chow BL, Davis BR, Gruenert DC. Application of SFHR to gene therapy of monogenic disorders. Gene Therapy 2002;9(11):691-4. - PubMed
Gray 1991
    1. Gray A, Anionwu EN, Davies SC, Brozovic M. Mortality in sickle cell disease: the experience of a British centre. Journal of Clinical Pathology 1991;44(6):459-63. - PMC - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327(7414):557-60. - PMC - PubMed
Higgins 2008
    1. Higgins JPT, Altman DG (editors). Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors), Cochrane Handbook of Systematic Reviews of Intervention. Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
Kohn 2014
    1. Kohn DB. Clinical Research Study of Autologous Bone Marrow Transplantation for Sickle Cell Disease (SCD) Using Bone Marrow CD34+ Cells Modified With the Lenti/ßAS3-FB Lentiviral Vector. https://clinicaltrials.gov/show/NCT02247843.
Lezcano 2006
    1. Lezcano NE, Odo N, Kutlar A, Brambilla D, Adams RJ . Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke 2006;37(6):1424-6. - PubMed
Manci 2003
    1. Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J Jr, et al. Causes of death in sickle cell disease: an autopsy study. British Journal of Haematology 2003;123(2):359-65. - PubMed
Mankad 2001
    1. Mankad VN. Exciting new approaches for pathophysiologic mechanisms of sickle cell disease. Pediatric Pathology and Molecular Medicine 2001;20(1):1-13. - PubMed
May 2000
    1. May C, Rivella S, Callegari J. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human betaglobin. Nature 2000;406(6791):82-6. - PubMed
Nathan 2001
    1. Nathan S. Gene Therapy for Sickle-Cell Disease? Science News 2001;160(24):372.
Ohene‐Frempong 1994
    1. Ohene-Frempong K, Nkrumah FK. Sickle cell disease: basic principles and clinical practice. New York: Raven Press Ltd, 1994.
Persons 2003
    1. Persons DA, Nienhuis AW. Gene therapy for the hemoglobin disorders. Current Hematology Reports 2003;2(4):348-55. - PubMed
Platt 1991
    1. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease. Rates and risk factors. New England Journal of Medicine 1991;325(24):11-6. - PubMed
Platt 1994
    1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. New England Journal of Medicine 1994;330(23):1639-43. - PubMed
Postnote 2005
    1. Postnote. Gene Therapy. UK Parliamentary Office of Science and Technology (www.parliament.uk/post) (accessed 07 July 2008);(Number 240).
Powars 1983
    1. Powars D, Overturf G, Turner E. Is there an increased risk of Haemophilus influenzae septicemia in sickle cell anaemia? Pediatrics 1983;71(6):927-31. - PubMed
Powars 2002
    1. Powars DR, Hiti A, Ramicone E, Johnson C, Chan L. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic and genetic factors. American Journal of Hematology 2002;70(3):206-15. - PubMed
Ribeil 2017
    1. Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, et al. Gene therapy in a patient with sickle cell disease. New England Journal of Medicine 2017;376(9):848-55. - PubMed
Serjeant 1992
    1. Serjeant GR. Sickle cell disease. 2nd revised edition. Oxford: Oxford University Press, 1992.
Serjeant 1993
    1. Serjeant GR, Serjeant BE. Management of sickle cell disease; lessons from the Jamaican Cohort Study. Blood Reviews 1993;7(3):137-45. - PubMed
Steinberg 2003
    1. Steinberg MH, Barton F, Casto O, Pegelow CH, Ballas SK, Kutler A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289(13):1645-51. - PubMed
WHO 2006
    1. World Health Organization. Sickle-cell anaemia. Report A59/9. Provisional agenda item 11.4. 59th World Health Assembly. www.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf (accessed 06 June 2008).

References to other published versions of this review

Olowoyeye 2010
    1. Olowoyeye A, Okwundu CI. Gene therapy for sickle cell disease. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No: CD007652. [DOI: 10.1002/14651858.CD007652.pub2] - DOI - PubMed
Olowoyeye 2012
    1. Olowoyeye A, Okwundu CI. Gene therapy for sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No: CD007652. [DOI: 10.1002/14651858.CD007652.pub3] - DOI - PubMed
Olowoyeye 2014
    1. Olowoyeye A, Okwundu CI. Gene therapy for sickle cell disease. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No: CD007652. [DOI: 10.1002/14651858.CD007652.pub4] - DOI - PubMed
Olowoyeye 2016
    1. Olowoyeye A, Okwundu CI. Gene therapy for sickle cell disease. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No: CD007652. [DOI: 10.1002/14651858.CD007652.pub5] - DOI - PubMed
Olowoyeye 2018
    1. Olowoyeye A, Okwundu CI. Gene therapy for sickle cell disease. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No: CD007652. [DOI: 10.1002/14651858.CD007652.pub6] - DOI - PubMed

Publication types